Literature DB >> 711337

Bacteriology of human experimental gingivitis: effect of plaque and gingivitis score.

W J Loesche, S A Syed.   

Abstract

The plaque flora isolated from discrete dentogingival sites during a human gingivitis experiment was analyzed as a function of the plaque score and of the gingivitis score. When the gingivitis score was plotted as a function of the plaque score, a nonbleeding gingivitis was associated with a proportional increase in the Actinomyces sp. at the expense of the Streptococcus sp. In particular, the percentage of Actinomyces israelii increased significantly, while the percent Streptococcus sanguis decreased significantly. A. israelii also increased significantly when a bleeding gingivitis developed. When the plaque score was plotted as a function of the gingivitis score, A. israelii increased significantly as the nonbleeding gingivitis developed, but A. viscosus and Bacteroides melaninogenicus increased significantly when the bleeding gingivitis developed. The availability of a sufficient number of plaques with a plaque score of 2.0 permitted the examination of the interrelationship of gingivitis and flora minus the effect of plaque biomass. The bacteriological profile showed that when bleeding occurred, the levels and proportions of A. viscosus and B. melaninogenicus increased significantly. These findings raise the possibility that proportional changes in the gingival plaque flora may uniquely contribute to the development of gingival inflammation in this experimental model.

Entities:  

Mesh:

Year:  1978        PMID: 711337      PMCID: PMC422072          DOI: 10.1128/iai.21.3.830-839.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  EXPERIMENTAL GINGIVITIS IN MAN.

Authors:  H LOE; E THEILADE; S B JENSEN
Journal:  J Periodontol       Date:  1965 May-Jun       Impact factor: 6.993

2.  REQUIRED ROLE OF BACTEROIDES MELANINOGENICUS IN MIXED ANAEROBIC INFECTIONS.

Authors:  S S SOCRANSKY; R J GIBBONS
Journal:  J Infect Dis       Date:  1965-06       Impact factor: 5.226

3.  Degradation of collagenous substrates by Bacteroides melaninogenicus.

Authors:  R J GIBBONS; J B MACDONALD
Journal:  J Bacteriol       Date:  1961-04       Impact factor: 3.490

4.  Lymphocyte blastogenesis to plaque antigens in human periodontal disease. I. Populations of varying severity of disease.

Authors:  N P Lang; F N Smith
Journal:  J Periodontal Res       Date:  1977-07       Impact factor: 4.419

Review 5.  The role of immunology in periodontal disease.

Authors:  R J Nisengard
Journal:  J Periodontol       Date:  1977-09       Impact factor: 6.993

6.  Cell mediated immune responses to plaque antigens during experimental gingivitis in man.

Authors:  F N Smith; N P Lang; H A Löe
Journal:  J Periodontal Res       Date:  1978-05       Impact factor: 4.419

Review 7.  Microbiology of periodontal disease -- present status and future considerations.

Authors:  S S Socransky
Journal:  J Periodontol       Date:  1977-09       Impact factor: 6.993

8.  Lymphoproliferative response during resolution and recurrence of naturally occurring gingivitis.

Authors:  M R Patters; N Sedransk; R J Genco
Journal:  J Periodontol       Date:  1977-07       Impact factor: 6.993

9.  The predominant cultivable microflora of advanced periodontitis.

Authors:  J Slots
Journal:  Scand J Dent Res       Date:  1977 Jan-Feb

10.  Bacteriology of human experimental gingivitis: effect of plaque age.

Authors:  S A Syed; W J Loesche
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

View more
  42 in total

1.  Changes in periodontal health status are associated with bacterial community shifts as assessed by quantitative 16S cloning and sequencing.

Authors:  Purnima S Kumar; Eugene J Leys; Jennifer M Bryk; Francisco J Martinez; Melvin L Moeschberger; Ann L Griffen
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

2.  Purification and characterization of levanase from Actinomyces viscosus ATCC 19246.

Authors:  T Igarashi; M Takahashi; A Yamamoto; Y Etoh; K Takamori
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

3.  Role of surface fimbriae (fibrils) in the adsorption of Actinomyces species to saliva-treated hydroxyapatite surfaces.

Authors:  W B Clark; E L Webb; T T Wheeler; W Fischlschweiger; D C Birdsell; B J Mansheim
Journal:  Infect Immun       Date:  1981-09       Impact factor: 3.441

4.  Adsorbed salivary proline-rich protein 1 and statherin: receptors for type 1 fimbriae of Actinomyces viscosus T14V-J1 on apatitic surfaces.

Authors:  R J Gibbons; D I Hay; J O Cisar; W B Clark
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

5.  Phosphorylating enzymes involved in glucose fermentation of Actinomyces naeslundii.

Authors:  N Takahashi; S Kalfas; T Yamada
Journal:  J Bacteriol       Date:  1995-10       Impact factor: 3.490

6.  Effects of estradiol and progesterone on Bacteroides melaninogenicus and Bacteroides gingivalis.

Authors:  K S Kornman; W J Loesche
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

7.  Mannose-contaminating agglutinin for Actinomyces viscosus and Actinomyces naeslundii.

Authors:  R P Ellen; W L Leung; E D Fillery; D A Grove
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

8.  In vitro stimulation of immunoglobulin production from human peripheral blood lymphocytes by a soluble preparation of Actinomyces viscosus.

Authors:  D F Mangan; D E Lopatin
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

9.  Cell-mediated cytotoxicity against rat fibroblasts induced by Actinomyces viscosus.

Authors:  R Gaegauf-Zollinger; J J Burckhardt; R Gmür; B Guggenheim
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

10.  Specific inhibition of adsorption of Actinomyces viscosus T14V to saliva-treated hydroxyapatite by antibody against type 1 fimbriae.

Authors:  W B Clark; T T Wheeler; J O Cisar
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.